Publication of a paper in Nature Biomedical Engineering highlights improved delivery and efficacy of therapeutics using Evox Therapeutics’ targeted exosomes
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Article Date
May 20, 2024
This article is featured on another website.
Go to article
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
June 1, 2026
Chime Biologics and Daewoong Pharmaceutical Enter Strategic Partnership to Advance Dupilumab Biosimilar Development and Commercialization in Global Markets
June 1, 2026